BioSpace News Archive

Drug Development

New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical Evaluation

Biotechnology company Inventprise announced that a Phase 1/2 clinical study of its 25-valent pneumococcal conjugate vaccine has begun in Halifax, Canada.

November 10, 2022
·
3 min read
Drug Development

Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic Gout at American College of Rheumatology Annual Meeting, Nov. 10 – 14, in Philadelphia, PA

Atom Bioscience announced that it will present final dated data from its Phase 2a clinical trial of its small molecule URAT1 inhibitor for treatment of chronic gout at the American College of Rheumatology annual meeting, Convergence 22, in Philadelphia, PA, Nov. 10-14.

November 10, 2022
·
4 min read
Business

Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update

Daré Bioscience, Inc., a leader in women’s health innovation, reported financial results for the quarter ended September 30, 2022 and provided a company update.

November 10, 2022
·
16 min read
Opthea to Present at Jefferies 2022 London Healthcare Conference

Opthea Limited announced that Chief Executive Officer Dr. Megan Baldwin will present at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 7:25 AM GMT.

November 10, 2022
·
2 min read
Biotech Beach

MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting

MannKind Corporation announced that it will present data from two posters on November 10 during the 22nd Annual Diabetes Technology Meeting’s virtual poster session.

November 10, 2022
·
4 min read
Pharm Country

OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease

OKYO Pharma Ltd announced that it will host a Key Opinion Leader event, “Introducing OK-101 as a Potential Treatment for Dry Eye Disease” on Monday, November 14, 2022 at 8:00 am Eastern Time.

November 10, 2022
·
4 min read
Policy

Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

Asieris Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the Investigational New Drug application for its oral drug APL-1401 for the treatment of moderately-to-severely active ulcerative colitis.

November 10, 2022
·
2 min read
BioForest

NanoString to Webcast Presentations from Two Upcoming November 2022 Healthcare Conferences

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that company management is scheduled to webcast presentations from two upcoming healthcare conferences.

November 10, 2022
·
2 min read
MolecuLight Featured in 10 Presentations and Posters at the AAWC 2022 Annual Conference

MolecuLight Inc. announces that its technology will be featured in over 10 clinical presentations and posters at the American Association of Wound Care 2022 Annual Conference, titled Technology in Wound Care.

November 10, 2022
·
5 min read
Pharm Country

BD Board Increases Dividend for 51st Consecutive Year

The Board of Directors of BD has declared a quarterly dividend of $0.91 per common share, an increase of 4.6% from the previous quarter. The dividend will be payable on Dec. 30, 2022 to holders of record on Dec. 9, 2022.

November 10, 2022
·
2 min read